495 Basal cell carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies

by Geoffrey Gibney, Ari VanderWalde, Joanne Xiu, Joseph Drabick, Gino In, Steven O’Day, Kelsey Poorman, W Korn
Published 2020-11-01

A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metasta...

by Matias A. Bustos, Rebecca Gross, Negin Rahimzadeh, Hunter Cole, Linh T. Tran, Kevin D. Tran, Ling Takeshima, Stacey L. Stern, Steven O’Day, Dave S. B. Hoon
Published 2020-11-01

479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results

by Andrea Bullock, Justin Moser, Daruka Mahadevan, Michael Gordon, Przemyslaw Twardowski, Apostolia Tsimberidou, Breelyn Wilky, Waldo Ortuzar Feliu, Anthony El-Khoueiry, Steven O’Day, Bruno Bockorny, Katherine Rosenthal
Published 2021-11-01

Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis

by Matias A. Bustos, Kevin D. Tran, Negin Rahimzadeh, Rebecca Gross, Selena Y. Lin, Yoshiaki Shoji, Tomohiro Murakami, Christine L. Boley, Linh T. Tran, Hunter Cole, Daniel F. Kelly, Steven O’Day, Dave S. B. Hoon
Published 2020-06-01